• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Persistent sore throat could be larynx cancer warning

Bioengineer by Bioengineer
January 29, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

GPs should consider larynx cancer when patients report a persistent sore throat, particularly when combined with other seemingly low-level symptoms.

A persistent sore throat combined with shortness of breath, problems swallowing or earache is a greater warning sign of laryngeal cancer than hoarseness alone, new research concludes.

Led by the University of Exeter, a study of more than 800 patients diagnosed with cancer of the larynx has found more than a five per cent risk of cancer from a persistent sore throat combined with one of these other symptoms. This compares with 2.7% risk for hoarseness alone.

The research, funded by NIHR and published today in BJGP aims to facilitate earlier detection of cancer, which is key in getting the best survival rates and health outcomes for patients. Currently, NICE guidelines recommend investigation for persistent hoarseness or an unexplained neck lump. The new research gives greater insight into the combinations of symptoms GPs should be alert to when deciding who should be investigated for cancer.

Professor Willie Hamilton, of the University of Exeter Medical School, is one of the authors. He said: “This research matters – when NICE guidance for cancer investigation was published there was no evidence from GP practices to guide this – nor to inform GPs. Crucially, hoarseness serious enough to be reported to GPs does warrant investigation. Furthermore, our research has shown the potential severity of some symptom combinations previously thought to be low-risk. “

The research was conducted using patient records for more than 600 GP practices as part of the UK’s Clinical Practice Research Datalink.

Each year, more than 1,700 people were diagnosed with cancer of the larynx. Of those, 80 per cent were male. The number has risen by almost a third over the past 20 years, with tobacco and alcohol use strongly linked to the disease.

Lead author Dr Elizabeth Shephard, of the University of Exeter Medical School, said: “The UK still lags well behind the rest of Europe on cancer survival rate – although our research is part of a body of work that is leading to significant improvements. Theres still some way to go and the results of this study really highlight the need to improve the current recommendations for all of the head and neck cancers – which are either incomplete or absent.”

The full paper is entitled ‘Recognising laryngeal cancer in primary care:
a large case-control study using electronic records’.

###

Media Contact
Louise Vennells
[email protected]
01-392-724-927
http://dx.doi.org/10.3399/bjgp19X700997

Tags: cancerDiagnosticsMedicine/HealthPain
Share12Tweet8Share2ShareShareShare2

Related Posts

Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer

September 7, 2025

Phase 2 IDeate-Lung01 Trial Shows Ifinatamab Deruxtecan Achieves High Response Rates in Previously Treated Extensive-Stage Small Cell Lung Cancer

September 7, 2025

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

September 7, 2025

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Leaf Beetle Evolution Boosts Defense Against Shared Wasp

Evaluating Impact of Environment on Kenyan Donkey Welfare

Protecting Youth from the Risks of Sports Betting Advertising in Canada

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.